Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 1;121(4):434-443.
doi: 10.1097/HP.0000000000001462.

Evaluation of Radiation-induced Pleural Effusions after Radiotherapy to Support Development of Animal Models of Radiation Pneumonitis

Masooma Aqeel  1 , Meetha Medhora, Elizabeth Gore, Jenna Borkenhagen  2 , Slade Klawikowski  2 , Daniel Eastwood  3 , Anjishnu Banerjee  3 , Elizabeth R Jacobs
Affiliations

Evaluation of Radiation-induced Pleural Effusions after Radiotherapy to Support Development of Animal Models of Radiation Pneumonitis

Masooma Aqeel et al. Health Phys. .

Abstract

Not all animal models develop radiation-induced pleural effusions (RIPEs) as a form of radiation-induced lung injury (RILI). Such effusions are also not well characterized in humans. The purpose of this study is to identify occurrences of RIPE in humans, provide justification for development of relevant animal models, and further characterize its risk factors in cancer patients. We also aim to identify dose thresholds for cardiopulmonary toxicity in humans to shed light on possible pathogenic mechanisms for RIPEs. We carried out a retrospective review of medical records of 96 cancer patients receiving thoracic irradiation (TRT) at our institution. Fifty-three (53%) patients developed a new pleural effusion post TRT; 18 (19%) had RIPE; and 67% developed RIPE ipsilateral to the site irradiated. None developed "contralateral only" effusions. Median time to development was 6 mo (IQR; 4-8 mo). Of 18, 8 patients (44%) had concomitant asymptomatic (radiographic only) or symptomatic radiation pneumonitis and pericardial effusion. Dosimetric factors, including combined and ipsilateral mean lung dose (MLD), were significantly associated with increased risk of RIPE. Angiotensin converting enzyme inhibition, steroids, or concurrent chemotherapy did not modify incidence of RIPE. Our results substantiate the occurrence and incidence of RIPEs in humans. In cancer patients, a median time to development of effusions around 6 mo also supports the onset of RIPEs concurrent with radiation pneumonitis. Future work needs to include large populations of cancer survivors in whom delayed RIPEs can be tracked and correlated with cardiovascular changes in the context of injury to multiple organs.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1:
Figure 1:
Comparison of percentage volume of lung for those who developed RIPE vs. all others. The % of lung that received ≥ 5 Gy, ≥ 20 Gy or ≥ 30 Gy are all likely to be higher for patients who develop RIPE.
See this image and copyright information in PMC

References

    1. American Thoracic Society (ATS) Guideline. Management of malignant pleural effusions. Am J Respir Crit Care Med. November 2000;162(5):1987–2001 - PubMed
    1. Bachman AL, Macken K. Pleural effusions following supervoltage radiation for breast carcinoma. Radiology. May 1959;72(5):699–709 - PubMed
    1. Borkenhagen J, Rapp C, Klawikowski S, Rein L, Gore E. Early cardiotoxicity in Thoracic Radiation Therapy for Lung and Esophageal Cancer. October 2016
    1. Deas SD, Huprikar N, Skabelund A. Radiation exposure and lung disease in today’s nuclear world. Curr Opin Pulm Med. March 2017;23(2):167–172 - PubMed
    1. Fukada J, Shigematsu N, Ohashi T, Shiraishi Y, Takeuchi H, Kawaguchi O, Kitagawa Y. Pericardial and pleural effusions after definitive radiotherapy for esophageal cancer. J Radiat Res. 2012;53(3):447–53 - PubMed

Publication types